ArtVentive Medical conducts First Human Clinical Study with EOS Peripheral vascular occlusion device

ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company has conducted its First Human Clinical Study with its EOS Peripheral vascular occlusion device. The study involved six male patients who had conditions related to venous peripheral disease, known as varicocele. The patients were infertile and suffered pain in the low pelvic area requiring venous occlusion of their spermatic or gonadal veins. The trial was pivotal in meeting the Company's goals, with a reported 100% acute procedural and clinical success providing a predictable, immediate occlusion of all targeted blood vessels. The study demonstrated the device's accuracy, safety and effectiveness.

The Study was performed by Dr. Adrian Ebner, of the Italian Clinic in Asuncion, Paraguay and Dr. Anthony Venbrux, Director of the Vascular and Interventional Radiology Division at the George Washington University Medical Center, located in Washington, DC.

Dr. Rudakov, President and Chief Technology Officer of ArtVentive Medical Group, Inc., was present during the trial and stated that, "The performance of the device showed the exceptional and unique advantage for occlusion of vessels in a wide spectrum of peripheral vascular applications. This is a noted milestone in the Company's quest to achieve its European commercialization of the EOS device."